Loading

logo

Journal of Cancer Immunology

ISSN: 2689-968X

Editorial Open Access
Volume 2 | Issue 1 | DOI: https://doi.org/10.33696/cancerimmunol.2.007

CTLA-4 and PD-L1 or PD-1 Pathways: Immune Checkpoint Inhibitors and Cancer Immunotherapy

Sachin Kumar Deshmukh1,*
  • 1Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA
+ Affiliations - Affiliations

Corresponding Author

Sachin Kumar Deshmukh, skdeshmukh@health.southalabama.edu

Received Date: January 11, 2020

Accepted Date: January 14, 2020

Citation:

Deshmukh SK. CTLA-4 and PD-L1/PD-1 Pathways: Immune Checkpoint Inhibitors and Cancer Immunotherapy. J Cancer Immunol. 2020; 2(1): 10-12.


Copyright: © 2020 Deshmukh SK. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Keywords

Immunotherapy, PD-L1, PD-1, CTLA-4, Cancer, Checkpoint inhibitor

Recommended Articles

Full Text
Cite
Download PDF
Author Information X

About Scientific Archives

Scientific Archives is a global publisher initiated with the mission of ensuring equal opportunity for accessing science to research community all over the world. Spreading research findings with great relevance to all channels without any barrier is our goal. We want to overcome the challenges of Open Access with ensured quality and transparency.

Read More